Therapeutic uses and indications of bosutinib/bosutinib

Bosutinib/Bosutinib is a tyrosine kinase inhibitor (TKI) specifically used for the treatment of chronic myelogenous leukemia (CML). It occupies an important position among the five approved drugs of the same type. Chronic myeloid leukemia is a malignant tumor caused by abnormal myeloid cell proliferation in the bone marrow. Bosutinib provides a new treatment option for this disease.

Bosutinib forms its unique mechanism of action by dually inhibitingSrc and ABL kinases and having the ability to target other related kinases. This mechanism not only enhances its anti-cancer effect, but also makes its side effects different from other similar drugs. The drug was approved by the FDA in 2013 and is suitable for patients who have been treated with one or more tyrosine kinase inhibitors but still need further treatment, especially those who have poor response or intolerance to traditional first-line drugs such as imatinib, nilotinib and dasatinib.

Although bosutinib failed to meet the primary endpoint in the initial clinical trial and was not approved as a first-line treatment, the follow-upBFORE study showed its effectiveness in patients with chronic phase CML. The good results of this study bring hope for the expanded indications of bosutinib, which means that more patients will be able to benefit from this treatment option in the future.

In terms of adverse reactions, bosutinib is characterized by a very low incidence of cardiovascular and thrombotic events, and relatively minor long-term safety issues. Most adverse reactions mainly appear in the first few months of treatment. However, gastrointestinal side effects were common with bosutinib in early clinical trials. Therefore, when treating with bosutinib, patients need to be closely monitored for gastrointestinal reactions and take necessary countermeasures.

Reference materials:https://pubmed.ncbi.nlm.nih.gov/30069626/